Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China

BACKGROUND: Patients treated with immunotherapy in the real-world may have significantly different responses to those meeting inclusion criteria for random controlled clinical studies. There is a partial overlap in approved indications for the use of the different immune checkpoint inhibitors (ICIs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Miao, Kang, Zhang, Xiaotong, Wang, Hanping, Si, Xiaoyan, Ni, Jun, Zhong, Wei, Zhao, Jing, Xu, Yan, Chen, Minjiang, Pan, Ruili, Wang, Mengzhao, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982065/
https://www.ncbi.nlm.nih.gov/pubmed/35392244
http://dx.doi.org/10.3389/fonc.2022.859938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982065/
https://www.ncbi.nlm.nih.gov/pubmed/35392244
http://dx.doi.org/10.3389/fonc.2022.859938

Ejemplares similares